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Purpose: Prostatic lesions on routine staining sometimes cause a diagnostic dilemma, especially when malignant tissue is limited 
and is mixed with benign prostatic glands or because of the presence of benign mimickers of carcinoma. The application of immuno-
histochemistry contributes a valuable differential diagnosis. This study aimed to evaluate a complete spectrum of various prostatic lesions 
and to supplement the histopathological diagnosis with immunohistochemistry in suspicious or atypical cases.
Methods: A total of 364 consecutive prostatic specimens were evaluated. Routine hematoxylin and eosin staining and immunohisto-
chemical staining against 34βE12 cytokeratin and proliferative marker (alpha-methylacyl-CoA-racemase, AMACR) were performed by 
use of the peroxidase antiperoxidase method.
Results: Benign prostatic hyperplasia was the most frequent finding and involved 285 patients (78.3%). Prostatitis (majority nonspecific) 
formed the predominant subgroup in nonneoplastic lesions (n=119, 32.7%). The incidence of carcinoma was low (n=73, 20.1%). Of 
the 26 atypical or suspicious cases, 18 cases were positive for high molecular weight cytokeratin (high molecular weight cytokeratin, 
HMWCK) only, 4 cases were positive for AMACR only, and 4 cases showed positivity for both HMWCK and AMACR. 
Conclusions: Biopsy remains the gold standard. However, as an adjunct to biopsy, proliferative markers and basal cell markers have 
value for resolving suspicious or atypical cases.
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INTRODUCTION
Benign prostatic hyperplasia (BPH) is a common urological 
condition in men. The prevalence of BPH increases from 20% 
at 40 years of age to 90% by the eighth decade of life [1]. Pros-
tatic carcinoma is globally the second most frequently diag-
nosed cancer and the sixth leading cause of cancer death in 
males [2]. In India, it constitutes about 5% of all male cancers 
[3]. Prostate-specific antigen (PSA), digital rectal examina-
tion, and transrectal ultrasound are the tools most commonly 
used to screen for prostate cancer. However, biopsy remains 
the gold standard for final diagnosis. Histological diagnosis of 
prostatic cancer is usually based on morphological features 
such as growth pattern, nuclear atypia, and absence of basal 
cells. However, this can be challenging, particularly when the 
malignant tissue is limited and is mixed with benign prostatic 
glands, or because of the presence of benign mimickers of 
carcinoma [4]. Therefore, the application of immunohisto-
chemistry (IHC) contributes valuable diagnostic information. 
 In recent years, several new markers, including the basal 
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cell marker high-molecular-weight-cytokeratin (HMWCK, 
clone 34βE12) and the prostate biomarker alpha-methylacyl-
CoA-racemase (AMACR), have been used as an adjunct to 
morphology in these diagnostically challenging cases with 
very high sensitivity and specificity. The accurate pathological 
evaluation of prostatic lesions is essential, because the sub-
ject of prostatic disease is fraught with doubts, uncertainties, 
and apparent contradictions [2,5].
 This study was undertaken to evaluate the complete spec-
trum of various prostatic lesions and to study the role of 34βE12 
and AMACR in different benign and malignant lesions of the 
prostate, especially in suspicious or atypical cases whenever 
possible.
MATERIALS AND METHODS
All prostatic specimens received over a period of 18 months 
(January 2010 to June 2011) were analyzed with reference 
to light microscopic findings. The surgical specimens were 
taken through transurethral prostatectomy, transrectal ultra-
sound-guided biopsy, and open prostatectomy. The histology 
slides were prepared from original paraffin blocks and were 
stained by hematoxylin and eosin (H&E). The histological fea-
tures were correlated with clinical profile and PSA levels. H&E-
stained slides were examined thoroughly and a provisional 
diagnosis of each case was made. 
 For immunohistochemical staining, by antibodies against 
34βE12 and AMACR, the kit literature of the manufacturer 
(Dako, Glostrup, Denmark; AMACR IS060-Clone-13H4; HM-
WCK IS051-M0630, Clone-34βE12, Isotype-IgG1, kappa) was 
followed. Expression of 34βE12 cytokeratin was considered as 
cytoplasmic positivity of the basal cells of the prostatic epithe-
lium, and the continuity of basal cells was assessed. AMACR 
showed continuous dark, diffuse cytoplasmic staining of the 
glandular epithelium. After the provisional diagnosis, a final 
diagnosis was made by the assessment of basal cell staining 
by 34βE12 and proliferative activity by AMACR.
RESULTS
The present study constituted a total of 364 cases. All prostatic 
specimens were broadly classified into nonneoplastic and 
neoplastic. Each category was then subclassified into specific 
types according to the standard classification systems. The 
age distribution of nonneoplastic and neoplastic lesions is 
depicted in Table 1.
 BPH was the most frequent finding and was observed in 
285 of the 364 cases (78.3%). Maximum numbers of lesions 
were seen in the age group of 61 to 70 years with an average 
age at presentation of 68.6 years. BPH alone was seen in 126 
cases (34.6%), whereas BPH was associated with acute and 
chronic prostatitis in 119 cases (32.7%), granulomatous pros-
tatitis in 13 (3.6%), basal cell hyperplasia (BCH) in 14 (3.9%), 
infarct in 2 (0.6%), squamous metaplasia in 3 (0.8%), and low-
grade prostatic intraepithelial lesions in 2 (0.6%). Six cases of 
atypical adenomatous hyperplasia (AAH) and 2 of atrophy 
constituted 1.7% and 0.6% of the total cases, respectively. No 
case of tubercular prostatitis was seen during our study pe-
riod. This practically nonexistent tubercular prostatitis in our 
series was attributed to early diagnosis and better availability 
of the drugs.
 The majority of cases in the neoplastic group were encoun-
tered in the age group of 71 to 80 years with a mean age of 
68.7 years. Histologically, of 79 neoplastic lesions, prostatic 
carcinoma formed the bulk with 73 of the total cases (20.1%), 
followed by 2 cases each of prostatic intraepithelial neoplasia 
(PIN) and rhabdomyosarcoma and 1 case each of leiomyoma 
and cystadenoma. 
 Prostatic adenocarcinoma accounted for almost all neo-
plasms of the prostate gland, accounting for 73 of 79 neoplastic 
lesions (92.4%). All cases of prostatic adenocarcinoma exhib-
ited different growth patterns and were categorized depend-
ing on the primary, secondary, or tertiary pattern. The most 
common pattern seen in this study was angulated glands in 
45 cases (61.6%), followed by a fused glandular pattern in 24 
cases (32.8%) and a cribriform pattern in 22 cases (30.1%). A 
sheeting pattern was observed in 17 cases (23.3%), a hyperne-
phroid pattern in 15 cases (20.6%), comedonecrosis in 9 cases 
(12.3%), and a single separate uniform glandular pattern in 4 
cases (5.5%). Perineural invasion was seen in 31 cases (42.5%). 
 Of the 73 cases of prostatic adenocarcinoma, Gleason grad-
ing was done in 68 cases. The majority of cases were of an in-
termediate grade (n=35, 51.5%), followed by low grade (n=19, 
27.9%) and high grade (n=14, 20.6%). No grading and scoring 
was done in 5 cases because of the paucity of tissue and lack 
of specific pattern. The tumor cells showed features such as 
Table 1. Age distribution of the patients 
Age (yr) Nonneoplastic, n (%) Neoplastic, n (%)
≤50 6 (2.11) 4 (5.06)
51–60 53 (18.60) 12 (15.19)
61–70 111 (38.95) 26 (32.91)
71–80 87 (30.53) 27 (34.18)
81–90 24 (8.42) 9 (11.39)
>90 2 (0.70) 1 (1.27)
Not recorded 2 (0.70) 0 (0)
Total 285 (78.30) 79 (21.70)
Garg, et al. Histopathological spectrum in prostatic specimens
148
PROSTATE INTERNATIONAL
http://dx.doi.org/10.12954/PI.13026
nuclear enlargement and hyperchromasia with prominent 
nucleoli at places, and these cells were seen infiltrating the 
stroma. 
 Of the 26 atypical or suspicious cases, 18 were positive for 
HMWCK only, 4 cases were positive for AMACR only, and 4 
cases showed positivity for both HMWCK and AMACR. Thus, 
on the basis of the IHC, of 2 cases of BPH with suspicious focus, 
one turned out to be BPH and the other adenocarcinoma. In 
the other cases the diagnostic error was due to benign mim-
ickers of prostate cancer, which included AAH, BCH, and atro-
phy. Of 6 cases of BPH with AAH, 4 were finally categorized as 
AAH and 2 turned out to be PIN. Of 14 cases of BCH, 11 cases 
were labelled as BCH and 3 as carcinoma, respectively. No 
discrepancy was noted in cases of atrophy and PIN. Twenty 
cases each of BPH and carcinoma were selected for IHC, keep-
ing the cost factor in mind, and the results were concordant 
(Table 2). After IHC application, the diagnosis was modified 
and is shown in Table 3.
 Serum PSA levels were measured in 185 cases, of which 132 
were benign and 53 were malignant. PSA levels > 20 ng/mL 
were seen in 17 benign cases (12.9%) and 45 malignant cases 
(84.9%). On comparison of PSA levels of > 20 ng/mL in non-
neoplastic versus neoplastic lesions, a P-value of 0.005 was 
obtained, which is highly significant. Thus, we conclude that 
a PSA value of > 20 ng/mL is highly suggestive of carcinoma 
of the prostate.
 In our study the most common clinical diagnosis in non-
neoplastic lesions was BPH (272 cases), with a positive predic-
tive value of 90.1%. The diagnosis of carcinoma of the prostate 
was made in 88 cases, with a negative predictive value of 94.5% 
and a low positive predictive value of 67.1%.
DISCUSSION
Prostatic specimens constitute a good percentage of the sur-
gical pathology workload. This study was undertaken to eval-
uate the various histological lesions in prostatic specimens. 
 The age of the patients in our study ranged from 7 years to 
93 years; however, the predominant population was in the 6th 
to 7th decade with a mean age of 68.6 years. No significant 
difference was noted in the mean age of the nonneoplastic 
and neoplastic groups. The results of the present study agree 
with the studies by George and Thomas [6], in which the 
mean age was 66.81 years, and by Barakzai et al. [7], in which 
the mean age was 66.9 years. The decline in the number of 
cases beyond the age of 80 years reflects the average life span 
of people in our country. 
 In our study, of 364 cases, 285 (78.3%) were nonneoplastic 
lesions, whereas neoplastic lesions constituted 79 of the total 
cases (21.7%). This agrees with the studies conducted by Mit-
tal et al. [8],  Anjorin et al. [9], and George et al. [6], in which 
nonneoplastic lesions formed the bulk of the cases. These 
results are shown in Table 4. However, the incidence of neo-
plastic lesions was relatively higher in our study than in the 
other studies. Various factors can contribute to this disparity. 
For example, in recent times, the incidence rates of prostate 
carcinoma have been influenced by the diagnosis of cancer in 
early stages. Moreover, this study was carried out in a tertiary 
health institution, which puts a high selective index on the 
data because the heath center acts as a referral center. 
 Prostatitis formed the predominant subgroup in the non-
neoplastic lesions with 132 of 364 cases (36.3%). Mittal et al. 
[8] in a study of 185 prostatic specimens reported that pros-
tatitis constituted 38.4% of the cases, of which 26.3% of cases 
were chronic prostatitis, and acute prostatitis with or without 
Table 2. Showing histopathological and final diagnosis after 
IHC 
Histopathological diagnosis HMWCK AMACR
Final diagnosis 
(after IHC)
Proven BPH (n=20) 20 - BPH
Proven carcinoma (n=20) - 20 Carcinoma
Grey zone
BPH with suspicious focus (n=2) 1 - BPH
- 1 Carcinoma
BCH (n=14) 11 - BCH
- 3 Carcinoma
AAH (n=6) 4 - AAH
2 2 PIN
Atrophy (n=2) 2 - Atrophy
LGPIN (n=2) 2 2 PIN
IHC, immunohistochemistry; HMWCK, high molecular weight cytokera-
tin; AMACR, alpha-methylacyl-CoA-racemase; BPH, benign prostatic hy-
perplasia; BCH, basal cell hyperplasia; AAH, atypical adenomatous hy-
perplasia; PIN, prostatic intraepithelial neoplasia; LGPIN, low grade pros-
tatic intraepithelial neoplasia.
Table 3. Showing histopathological and final diagnosis after 
IHC (n=66)
Case
Histopathological  
diagnosis (before IHC)
Final diagnosis  
(after IHC)
BPH 20 21
BCH 14 11
AAH 6 4
Atrophy 2 2
PIN 2 4
Carcinoma 22 24
IHC, immunohistochemistry; BPH, benign prostatic hyperplasia; BCH, 
basal cell hyperplasia; AAH, atypical adenomatous hyperplasia; PIN, 
prostatic intraepithelial neoplasia.
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abscess formation was noted in 12.1% of cases. 
 Granulomatous prostatitis was seen in 13 of 364 cases (3.6%). 
One of 13 cases showed granulomas with Langhans’ giant 
cells and small foci of necrosis; however, Ziehl Nelsen (20%) 
staining in this case was negative for acid fast bacilli and no 
history of Bacillus Calmette–Guérin vaccine instillation could 
be elicited. Also, the granulomas were seen in close proximity 
to acini and thus were finally labeled as a nonspecific type. 
In all other cases, nonspecific granulomas composed of a 
collection of epithelioid cells were present around the rup-
tured acini. No granuloma was thus labelled as tubercular. 
The practically nonexistent tubercular prostatitis in our series 
could be explained by the fact that the incidence of tubercular 
prostatitis has been reduced because of early diagnosis and 
better drugs available for treatment. Also, our center caters to 
a better socioeconomic group of society; hence, tuberculosis 
is rarely seen as a disseminated disease. 
 BCH was the second most common entity in the nonneo-
plastic group and accounted for 3.9% (14 cases) of the total 
cases. All cases had associated BPH. Thorson et al. [10] stud-
ied 500 needle core biopsy samples and found the incidence 
of BCH in the setting of usual nodular hyperplasia to be in the 
range of 3.1% to 8.9%. 
 The present study showed squamous metaplasia in only 3 
cases, accounting for 0.8% of the cases. Similar results were 
seen in a study done by Abdollahi and Ayati [11], who found 
squamous cell metaplasia in 4 cases (0.3%) in a study of 1,566 
prostatic specimens. 
 In the present study, 6 cases of AAH and 2 cases of atrophy 
were observed, constituting 1.7% and 0.6% of the sample, 
respectively. This is comparable to the reported incidence of 
less than 1% by Hameed and Humphrey [12], who stated that 
AAH is invariably an incidental histological finding, usually 
localized in the transition zone, and is thereby seen more 
often in transurethral prostatectomy chips. The peculiarity 
of these two processes is that they may be confused with the 
diverse patterns of prostatic adenocarcinoma. In general, 
routine microscopy helps us reach the correct diagnosis; 
however, ancillary IHC studies (HMWCK) may sometimes be 
needed to demonstrate the presence of basal cells in keeping 
with the benign nature of these two lesions.
 The age-specific prevalence of PIN is similar in almost all 
populations. High-grade PIN is generally accepted as a pre-
cursor lesion of carcinoma [13]. This statement holds true for 
our study because all the cases of high-grade PIN were seen 
with adenocarcinoma and no association was observed with 
BPH. However, owing to the paucity of cases of high-grade 
PIN in the present study, we cannot conclusively comment 
on this finding.
 The prevalence of prostatic carcinoma in the present study 
was 20.1%, i.e., 73 of 364 cases. Similar results were obtained 
by Anjorin et al. [9] and Rekhi et al. [14]. Most cases of prostate 
cancer are diagnosed after 50 years of age, but prostate cancer 
can be seen in younger adults. The frequency increases with 
age. In the present study, the age range was widespread (44–
93 years) with a mean of 68.7 years. However, the majority of 
cases (n = 26, 35.6%) were seen in the age group of 71 to 80 
years, closely followed by the age group of 61 to 70 years. Two 
cases were seen below the age of 50 years. The time trends 
in detection of carcinoma at an early age have been greatly 
affected because more and more latent cases are diagnosed 
with the increasing use of PSA, which can explain higher per-
centage of cases in the age group of 61 to 70 years (Table 4).
 Histological grade has been recognized as a powerful prog-
nostic predictor of prostate cancer. Various other studies in-
cluding ours highlight a score of 7 to 8 as a predominant score 
[6,15].
 Perineural invasion is regarded as pathognomonic of pros-
tate cancer if there is circumferential or intraneural invasion 
by the tumor cells [16]. A study conducted on 302 needle biop-
sies by Bastacky et al. [17] showed perineural invasion in 20% 
of biopsies with cancer. This correlates well with the present 
study in which perineural invasion was found in 31 of the 
malignant cases (42.5%) and was not observed in any of the 
Table 4. A comparison of the findings of the current study with 
other studies
Histopathological  
diagnosis
Mittal  
et al. [8]
Anjorin 
et al. [9]
George 
and  
Thomas [6]
Present 
study
Total no. of cases 185 801 1,163 364
Nodular hyperplasia 40.00 71.6 88.5 34.62
With prostatitis 38.39 11.2 - 32.69
Granulomatous prostatitis 1.62 - - 3.57
Nonspecific 3.57
Tubercular 0
Basal cell hyperplasia 5.4 - - 3.85
Infarct - - - 0.55
Squamous metaplasia 3.24 - - 0.82
Atypical adenomatous  
hyperplasia
2.16 - - 1.65
Atrophy 1.63 - - 0.55
Prostatic intraepithelial 
neoplasia
- - 0.6 0.55
Adenocarcinoma 7.02 17.2 10.9 20.05
Leiomyoma 0.54 - - 0.27
Rhabdomyosarcoma - - - 0.55
Cystadenoma - - - 0.27
Values are presented as percentage unless otherwise indicated.
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benign cases studied. 
 The correlation of PSA levels with nonneoplastic and neo-
plastic lesions was analyzed. PSA levels were available in 185 
cases (132 nonneoplastic and 53 neoplastic) only. This is be-
cause prostate biopsy in our institution is performed in symp-
tomatic patients as an outpatient procedure in a significant 
number of patients and PSA testing is not requested in these 
cases. 
 The IHC panel for prostatic carcinoma usually includes at 
least one basal cell–specific marker and the prostate cancer–
specific marker AMACR. The most commonly used basal cell–
specific markers in prostate cancer are HMWCK and clone 
34βE12. 
 Cytokeratin 34βE12 shows continuous, intact, circumfer-
ential staining of basal cells in benign and premalignant le-
sions but discontinuous staining in malignant lesions [18,19]. 
Negative staining must be interpreted with caution because 
cytokeratin is formalin sensitive and a progressive loss of 
immunoreactivity can be seen in prolonged formalin fixa-
tion. AMACR showed a continuous dark diffuse cytoplasmic 
staining or circumferential apical granular staining pattern in 
malignant prostatic lesions but little or no immunoreactivity 
in benign lesions [20] (Figs. 1–3).
 IHC markers (HMWCK and AMACR) were done in 66 cases 
in our study because the clinicians ordered markers in 26 sus-
picious or atypical cases. The other reason was the cost factor 
of the markers. 
 HMWCK was positive in all cases of BPH (100%), 1 case of 
BPH with suspicious focus, 11 cases of BCH, 4 cases of AAH, 
and 2 cases of atrophy, whereas AMACR was positive for all 
cases of prostate cancer (100%), 1 case of BPH with suspicious 
focus, and 3 cases of BCH. On the other hand, cases of BPH 
did not show AMACR positivity and HMWCK was completely 
negative in cases of prostate cancer. Jiang et al. [19] reported 
100% AMACR positivity in a study of 137 cases of prostate 
cancer. Lesions like BPH and adenosis were completely nega-
tive for this marker.
 In 6 of 26 suspicious or atypical cases, the diagnosis was 
changed on the basis of the IHC markers (HMWCK and 
AMACR). In 5 of the 6 cases the diagnosis was changed from 
nonneoplastic to neoplastic, whereas in 1 it was changed 
from neoplastic to nonneoplastic (BPH with suspicious focus 
to BPH). Immunostaining with both markers resolved these 
cases; thus, we inferred that both HMWCK and AMACR in-
crease the diagnostic efficacy.
 We conclude that proliferative activity and invasiveness in-
creases from the benign to the malignant end in the spectrum 
of prostatic lesions. IHC plays an important role in the diag-
nosis of prostatic lesions and helps to differentiate malignant 
glands from benign lesions, especially for lesions in the grey 
zone in routine histopathological study. Although the num-
ber of cases included in this study was 364, only 26 atypical 
or suspicious cases were encountered, which forms a small 
subgroup and is not very significant for reaching a definite 
conclusion.
A C
B
Fig. 1. (A) Benign prostatic hyperplasia (BPH) of the prostate 
with corpora amylacea (H&E, ×100). (B) BPH high molecular 
weight cytokeratin. (C) BPH alpha-methylacyl-CoA-racemase.
BA D
C
Fig. 3. (A) Gleason pattern 4 showing cells with clear cytoplasm 
(hypernephroid). (B) Inset showing perineural invasion (H&E, 
×100). (C) High molecular weight cytokeratin in cancer. (D) Cy-
toplasmic staining of alpha-methylacyl-CoA-racemase in epi-
thelial cells in a case of prostate cancer.
A C
B
Fig. 2. (A) High-grade prostatic intraepithelial neoplasia (PIN) 
showing cribriform pattern of the gland. Note the prominent 
nucleoli and intact basal cell layer (H&E, ×400). (B) PIN high 
molecular weight cytokeratin. (C) PIN alpha-methylacyl-CoA-
racemase.
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